A brief history of the formation of the concept of resistant depression and a detailed history of the use of irreversible non-selective MAOIs for this condition (on the occasion of the 70th anniversary of this group of antidepressants)
Suggested citation:
Danilov DS. [A brief history of the formation of the concept of resistant depression and a detailed history of the use of irreversible non-selective MAOIs for this condition (on the occasion of the 70th anniversary of this group of antidepressants)]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2022;(4):83-94. Russian
In this scientific historical review dedicated to the 70th anniversary of the beginning of the use of irreversible non-selective monoamine oxidase inhibitors (IMAO) in patients with depression, the history of the formation of the concept of resistant depression is briefly systematized; disagreements regarding the criteria of this concept are analyzed; the histories of studying the effectiveness and use of IMAO and their combination with tricyclic antidepressants are systematized in detail; different points of view regarding the rationality of such therapy are analyzed. The description of historical events covers almost a 60-year period – from the moment the first reports which appeared in the mid-60s of the XX century to the end of the second decade of the XXI century.
Keywords irreversible non-selective monoamine oxidase inhibitors; MAOIs; combination of MAOIs and TCAs; antidepressants; resistant depression; history of effectiveness assessment; history of usage
1. Smith JA. The use of the isopropyl derivative of isonicotinylhydrazine (marsilid) in the treatment of mental disease; A preliminary report. Am Practitioner Dig Treat. 1953;4(8):519–20. PMID: 13080562 2. Kamman GR, Freeman JG, Lucero RJ. The effect of l-isonicotynil-2-isopropyl hydrazine (IIH) on the behavior of long-term mental patients. J Nerv Ment Dis. 1953;118(5):391–407. DOI: https://doi.org/10.1097/00005053-195311000-00002 3. Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc. 1957;8:129–41. PMID: 13542681 4. Arnot R. Theory on the cause of psychoneurotic symptoms based on observations of their treatment with an energizer. Dis Nerv Syst. 1959;20(5, Part 2):49–52. PMID: 13663758 5. Ricken R, Ulrich S, Schlattmann P, Adli M. Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. Eur Neuropsychopharmacol. 2017;27(8):714–31. DOI: https://doi.org/10.1016/j.euroneuro.2017.04.003 6. Gillman PK. Monoamine oxidase inhibitors, dietary tyramine and drug interactions. PsychoTropical Commentaries. 2020;1:1–70. 7. Cole JO, Bodkin JA. MAO inhibitors: an option worth trying in treatment-resistant cases. Curr Psychiatry. 2002;1(6):40–7. 8. Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr. 2008;13(10):855–70. DOI: https://doi.org/10.1017/s1092852900016965 9. Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). 2018;125(11):1707–17. DOI: https://doi.org/10.1007/s00702-018-1932-y 10. Psikhiatriya: natsional'noe rukovodstvo. YuA Aleksandrovskii, NG Neznanov, editors. 2-e izd. Moscow: GEOTAR-Media; 2018. 1008 р. (In Russ.) 11. Divry P, Bobon J, Collard J, et al. Essai de chimiotherapie par l'imipramine des etats depressifs rebelles. Acta Neurol Psychiatr Belg. 1959;(59):951–7. (In French.) 12. Davidson J. The management of resistant depression. Br J Psychiatry. 1974;124(579):219–20. DOI: https://doi.org/10.1192/bjp.124.2.219-a 13. van Praag HM. Therapy-resistant depressions: biochemical and pharmacological considerations. Int J Psychiatry Med. 1975;6(1–2):99–111. DOI: https://doi.org/10.2190/3UN1-XLMK-RLGE-C4JF 14. Shaw DM, Hewland R. Correspondence: The management of resistant depression. Br J Psychiatry. 1973;123(575):489–90. DOI: https://doi.org/10.1192/bjp.123.4.489 15. Lapin IP. Proceedings: Antagonism of nicotinic acid and other kynurenines to antidepressants: one of the probable reasons of the therapy-resistance in depression? Act Nerv Super (Praha). 1974;16(4):260–1. PMID: 4548797 16. Overall JE. Methodologic issues in the epidemiology of treatment resistant depression. Contribution to epidemiology. Pharmakopsychiatr Neuropsychopharmakol. 1974;7(3):129–38. DOI: https://doi.org/10.1055/s-0028-1094411 17. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51(Suppl):39–47, discussion 48–50. PMID: 2112132 18. No authors. Colloque international. Les dépressions résistantes aux traitements antidépresseurs. Paris (France), 17 janvier 1986. Encephale. 1986;12(Spec No):187–262. (In French.) 19. Meltzer HY, Maes M, Elkis H. The biological basis of refractory depression. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD. Refractory depression: Current strategies and future directions. Chichester: John Wiley; 1994. р. 177–198. 20. Laage TA. Recognizing the drug-resistant patient in anxiety and depression. Med Clin North Am. 1988;72(4):897–909. DOI: https://doi.org/10.1016/s0025-7125(16)30751-9 21. Wilhelm K, Mitchell P, Boyce P, et al. Treatment resistant depression in an Australian context. I: The utility of the term and approaches to management. Aust N Z J Psychiatry. 1994;28(1):14– 22. DOI: https://doi.org/10.3109/00048679409075841 22. Moreno DH, Moreno RA, Calil HM. A Brazilian experience of treatment-resistant depression. Int Clin Psychopharmacol. 1994;9(Suppl 2):11–6. DOI: https://doi.org/10.1097/00004850-199406002-00003 23. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 (Suppl 13):23–9. PMID: 9402916 24. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–59. DOI: https://doi.org/10.1016/s0006-3223(03)00231-2 25. Souery D, Amsterdam J, de Montigny C, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9:83–91. DOI: https://doi.org/10.1016/s0924-977x(98)00004-2 26. Shamanina VM, Romel' TE, Kontsevoi VA, Akopova IL. Zatyazhnye depressii pri endogennykh psikhozakh. In.: EYa Shternberg, AB Smulevich, editors. Depressii. Voprosy kliniki, psikhopatologii, terapii (Doklady, predstavlennye na simpoziume, prokhodivshem 10–12 sentyabrya 1970 g. v g. Moskve. Moscow–Bazel': Upravlenie po vnedreniyu novykh lekarstvennykh sredstv i meditsinskoi tekhniki MZ SSSR, Farmatsevticheskaya firma SIBA-GEIGI, Institut psikhiatrii AMN SSSR; 1970. р. 59–73. (In Russ.) 27. Avrutskii GYa, Mosolov SN, Sharov AI. Sravnitel'naya effektivnost' timoanalepticheskoi terapii depressivnykh i depressivno-bredovykh sostoyanii pri faznoprotekayushchikh psikhozakh. Sotsial'naya i klinicheskaya psikhiatriya. 1991;1(1):84–91. (In Russ.) 28. Vovin RYa, Aksenova IO, Kyune G-E. Problema khronizatsii psikhozov i preodolenie terapevticheskoi rezistentnosti (na modeli depressivnykh sostoyanii). In: RYa Vovin, G-E Kyune, editors. Farmakoterapevticheskie osnovy reabilitatsii psikhicheski bol'nykh. Moscow: Meditsina; 1989. р. 151–81. (In Russ.) 29. Nuller YuL, Mikhalenko IN. Affektivnye psikhozy. Moscow: Meditsina; 1988. 264 р. (In Russ.) 30. Mosolov SN. Klinicheskoe primenenie sovremennykh antidepressantov. St. Petersburg: Meditsinskoe informatsionnoe agentstvo; 1995. 568 р. (In Russ.) 31. Kline S. Le traitement pratique de la dépression. Ann Med Psychol (Paris). 1965;123(1):53–70. (In French.) 32. Pare CM. Monoamine oxidase inhibitors in resistant depression. Int Pharmacopsychiatry. 1979;14(2):101–9. DOI: https://doi.org/10.1159/000468364 33. Nolen WA. Tranylcypromine in depression resistant to cyclic antidepressions. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(1–2):155–8. DOI: https://doi.org/10.1016/0278-5846(89)90012-2 34. Georgotas A, Friedman E, McCarthy M, et al. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry. 1983;18(2):195–205. PMID: 6830930 35. Prokhorova IS. Nekotorye aspekty differentsirovannoi terapii tsirkulyarnykh depressii. Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova [Zh Nevrol Psihiatr Im SS Korsakova]. 1985;85(4):570– 4. (In Russ.) 36. Kontsevoi VA, Andrusenko MP. Klinicheskaya gerontopsikhofarmakologiya: dostizheniya i problemy (obzor zarubezhnykh issledovanii). Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova [Zh Nevrol Psihiatr Im SS Korsakova]. 1989;89(9):127–38. (In Russ.) 37. Shamanina VM, Lobova EK. K sravnitel'noi otsenke deistviya niamida pri parenteral'nom i peroral'nom ego primenenii v klinike depressivnykh. Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova [Zh Nevrol Psihiatr Im SS Korsakova]. 1964;64(9):1408–13. (In Russ.) 38. Avrutskii GYa, Neduva AA. Lechenie psikhicheski bol'nykh: Rukovodstvo dlya vrachei. 2-e izd. Moscow: Meditsina; 1988. 528 р. (In Russ.) 39. Patten SB, Lupin DA, Boucher SA, Lamarre CJ. Pharmacologic management of refractory depression. CMAJ. 1992;146(4):483–7. PMID: 1737312 40. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry. 1992;53(1):5–11. 41. Birkenhäger TK, van den Broek WW, Mulder PG, et al. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients. J Clin Psychiatry. 2004;65(11):1505–10. DOI: https://doi.org/10.4088/jcp.v65n1110 42. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1531–41. DOI: https://doi.org/10.1176/ajp.2006.163.9.1531 43. Nolen WA, van den Broek WW, Birkenhäger TK. Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. Am J Psychiatry. 2007;164(3):524. DOI: https://doi.org/10.1176/ajp.2007.164.3.524 44. McGrath PJ, Stewart JW, Fava M, et al. Dr. McGrath and Colleagues Reply. Am J Psychiatry. 2007;164(3):524. 45. Schatzberg AF, Cole JO, DeBattista Ch. Manual of Clinical Psychopharmacology. AB Smulevich, SV Ivanov, editors. Moscow: MED press-inform; 2013. 608 р. (In Russ.) 46. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789–97. DOI: https://doi.org/10.1007/s40263-013-0097-3 47. Gillman PK. Tranylcypromine (parnate): a brief history and a enduring anomaly. 2014. URL: https://psychotropical.com/65-tranylcypromine-parnate-a-brief-history/ (accessed on: 20.08.2022). 48. Larsen JK, Krogh-Nielsen L, Brøsen K. The monoamine oxidase inhibitor isocarboxazid is a relevant treatment option in treatment-resistant depression-experience-based strategies in Danish psychiatry. Health Care: Current Reviews. 2016;4(2). DOI: https://doi.org/10.4172/2375-4273.1000168 49. Tsirkin SYu. Retsenziya na knigu “Novye rezul'taty v izuchenii depressii”. Pod red. G Khippiusa, Dzh L Klermana, N Matusseka, pri uchastii M Shmaussa, Berlin–Geidel'berg–N'yu-Iork–London–Parizh–Tokio, 1986, 263 р. (New Results in Depression Research. Ed. by H Hippius, GL Klerman, N Matussek. With the assistance of M Schmauss. Berlin–Heidelberg–New York–London–Paris–Tokyo: Verl. Springer, 1986. 263 p.). Zhurnal Nevrologii i Psikhiatrii imeni SS Korsakova [Zh Nevrol Psihiatr Im SS Korsakova]. 1989;89(9):149–52. (In Russ.) 50. Warneke L. Management of resistant depression. Can Fam Physician. 1996;42:1973–80. PMID: 8894244 51. White K. Tricyclic overdose in a patient given combined tricyclic-MAOI treatment. Am J Psychiatry. 1978;135(11):1411. DOI: https://doi.org/10.1176/ajp.135.11.1411 52. White K, Simpson G. The combined use of MAOIs and tricyclics. J Clin Psychiatry. 1984;45(7, Pt 2):67–9. PMID: 6376486 53. Poirier MF, Benkelfat C. Bonnes et mauvaises associations thérapeutiques dans le traitement des dépressions résistantes. Encephale. 1986;12(Spec No):225–30. (In French.) 54. Arana GW, Rosenbaum JF. Farmakoterapiya psikhicheskikh rasstroistv. SN Mosolov, editor. Moscow: Binom; 2004. 416 р. (In Russ.) 55. Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry. 1983;44(9, Pt 2):20–4. PMID: 6355073 56. Amsterdam JD, García-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84–90. DOI: https://doi.org/10.1002/(sici)1520-6394(1997)5:2<84::aid-da4>3.0.co;2-5 57. Berlanga C, Ortega-Soto HA. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord. 1995;34(3):187–92. DOI: https://doi.org/10.1016/0165-0327(95)00016-g 58. Schmauss M, Kapfhammer HP, Meyr P, Hoff P. Combined MAO-inhibitor and tri- (tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):523–32. DOI: https://doi.org/10.1016/0278-5846(88)90111-x 59. O'Brien S, McKeon P, O'Regan M. The efficacy and tolerability of combined antidepressant treatment in different depressive subgroups. Br J Psychiatry. 1993;162(3):363–8. DOI: https://doi.org/10.1192/bjp.162.3.363 60. Palaniyappan L, Insole L, Ferrier N. Combining antidepressants: a review of evidence. Adv Psychiatr Treat. 2009;15(2):90–9. DOI: https://doi.org/10.1192/apt.bp.107.004820 61. Schipper P, Vanmolkot L, Peeters FP. Combineren van klassieke monoamine-oxidaseremmer en tricyclisch anti-depressivum bij therapieresistente depressie: gevalsbeschrijving en literatuuroverzicht. Tijdschr Psychiatr. 2016;58(12):886–90. (In Dutch.) 62. Ferreira-Garcia R, da Rocha Freire RC, Appolinário JC, et al. Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant depression: A long-term study. J Clin Psychopharmacol. 2018;38(5):502–4. DOI: https://doi.org/10.1097/JCP.000000000000094
DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10410
Article Metrics
Metrics powered by PLOS ALM